BMRN
BIOMARIN PHARMACEUTICAL INC
NASDAQ · Healthcare · Biotechnology · US
$63.94
−1.75%Next report
Analyst consensus
- Next report date
- Oct 26, 2026
- EPS estimate
- $1.34
- Revenue estimate
- $1.0B
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- $1.20
- EPS estimate
- $0.95
- Revenue actual
- $989.7M
- Revenue estimate
- $932.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +19.0%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $94
- PT range
- $60 – $124
- Analysts
- 10
8 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $0.95 | $1.20 | Beat 26.72% | $989.7M |
| May 4, 2026 | $0.94 | $0.55 | Miss -41.49% | $766.0M |
| May 1, 2025 | $0.94 | $1.13 | Beat 20.21% | $745.1M |
| Feb 19, 2025 | $0.54 | $0.92 | Beat 70.37% | $738.2M |
| Feb 22, 2024 | $0.44 | $0.49 | Beat 11.36% | $646.2M |
| Nov 1, 2023 | $0.46 | $0.46 | In line | $586.0M |
| Feb 27, 2023 | -$0.07 | $0.36 | Beat 614.29% | $537.5M |
| Oct 26, 2022 | $0.37 | $0.45 | Beat 21.62% | $505.3M |
| Aug 3, 2022 | $0.43 | $0.59 | Beat 37.21% | $533.8M |
| Feb 23, 2022 | $0.03 | $0.03 | Beat 0.40% | $449.8M |
| Jul 28, 2021 | $0.30 | $0.53 | Beat 76.67% | $501.7M |
| Apr 29, 2021 | $0.32 | $0.56 | Beat 75.00% | $486.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 26, 2026